We're Making an Impact
OneWorld Health developed Paromomycin IM Injection (PMIM) as a safe, effective and low-cost alternative to previous kala-azar treatments. PMIM was approved by the governments of India and Nepal, and is included on the World Health Organization’s list of Essential Medicines.
Challenging Models - Changing Minds
OneWorld Health was founded by Drs. Victoria Hale and Ahvie Herskowitz in 2000, and received 501(c)(3) tax-exempt status in 2001, becoming the first nonprofit pharmaceutical company in the U.S. Since that time we’ve achieved a number of impressive milestones:
Oneworld Health's PMIM to treat kala-azar is registered by the government of Nepal.
OneWorld Health's safety and efficacy study of PMIM as a treatment for kala-azar in Bangladesh completes enrollment.
OneWorld Health becomes a drug development affiliate of PATH.
OneWorld Health receives educational grant from Sanofi Pasteur in India for advocacy program to help maintain polio free status in selected states of India.
OneWorld Health receives $1.9 million as part of a larger grant for the project led by DNDi, and in collaboration with TDR. The four-year long consortium project aims to boost strategies for control and eventual elimination of visceral leishmaniasis in India and Bangladesh.
OneWorld Health partners with A-Cube to develop DNA vaccines for numerous diseases starting with ETEC diarrheal diseases.
OneWorld Health partners with the Jharkhand State Department of Health to support soil transmitted helminth (STH) control initiative aimed at reducing chronic worm infection and high incidence among children in India.
PMIM is approved for the Essential Drug List of Nepal.
OneWorld Health partners with the Center for World Health and Medicine at Saint Louis University, and announce a joint research agreement to develop new drugs to combat diarrhea.
OneWorld Health, in collaboration with its partners, successfully completes the scientific work necessary to enable production of semisynthetic artemisinin - a key component of Artemisinin-based Combination Therapy (ACT), which has been recommended by the World Health Organization as the first line treatment for uncomplicated malaria. OneWorld Health and its partner sanofi-aventis announce start of production and distribution phase, with a goal to facilitate integration of semisynthetic artemisinin into the supply chain and ACTs by April 2012. Semisynthetic artemisinin will provide an affordable, stable, non-seasonal, complementary source of artemisinin, which should in turn stabilize price volatility, alleviate shortages and meet future global demand.
OneWorld Health partners with Anacor Pharmaceuticals to discover antibacterial compounds for treating bloody diarrhea (shigellosis).
The Food and Drug Administration (FDA) grants OneWorld Health phase 1 trials for iOWH032, a drug to treat secretory diarrheas as a result of diseases like cholera.
OneWorld Health receives an additional grant of ₤2,200,000 from DfID to fund existing projects and expand the diarrheal diseases portfolio.
OneWorld Health receives ₤5,000,000 (approximately $7,616,033 US) grant from the Department for International Development (DfID) in the United Kingdom to target neglected infectious diseases affecting the world's poorest people.
OneWorld Health receives grant of $10.7 million from the Bill and Melinda Gates Foundation to prepare for large-scale production and commercialization of semisynthetic artemisinin, a key ingredient in first line malaria treatments.
OneWorld Health completes a major Phase 4 pharmacovigilance study of PMIM for the treatment of kala-azar in India.
OneWorld Health completes, in collaboration with Rajendra Memorial Research Institute of Medical Sciences, a field research on VL in India (district of Bihar).
OneWorld Health extends kala-azar (visceral leishmaniasis) treatment campaign to Bangladesh and Nepal.
OneWorld Health begins collaboration with Novartis to discover and develop a novel therapy for secretory diarrhea, designed to prevent excessive loss of water from the body via the gastro-intestinal tract.
OneWorld Health completes its first screening campaign of the Roche proprietary compound library and identifies 40 new drug leads to treat childhood diarrhea.
OneWorld Health, BioFocus DPI and Roche collaborate in a project that screens 700,000 compounds from the Roche library to identify a potential new drug to combat Diarrheal Diseases.
OneWorld Health partners with synthetic biology innovator Amyris Biotechnologies, and leading pharmaceutical company sanofi-aventis to develop semisynthetic artemisinin, a key ingredient in first-line malaria treatments.
PMIM is approved for the Essential Drug List of Bangladesh.
OneWorld Health is named one of the Social Enterprises of the Year by Fast Company .
OneWorld Health launched the Phase 4 Program of Paromomycin IM Injection in India with the goal of developing a scalable, transferable access model for treatment of visceral leishmaniasis in India .
Paromomycin IM Injection is designated by the World Health Organization (WHO) for inclusion on its Model List for Essential Medicines.
In collaboration with Amyris, our Artemisinin Project partner, the malaria team completes due diligence and selects a contract manufacturing partner to scale-up the development process.
OneWorld Health receives approval for Paromomycin IM Injection from the Drug Controller General of India (DCGI) for the treatment of visceral leishmaniasis. Gland Pharma made the medicine available at-cost.
The antimalarial drug precursor, artemesinic acid, is produced in engineered yeast. This great technical achievement resulted from the unique three-way partnership between OneWorld Health, UC Berkeley and Amyris Biotechnologies.
A grant of US$46 million from the Bill & Melinda Gates Foundation funds OneWorld Health's Diarrheal Disease program to expand its unique research on new treatments to complement traditional approaches for fighting diarrhea.
OneWorld Health implements collaboration with BioFocus DPI; who will apply their medicinal chemistry expertise to identify new drug candidates for the Diarrheal Disease program.
A grant of US$10 million from the Bill & Melinda Gates Foundation funds OneWorld Health's program for paromomycin, through the approval and post-approval process.
OneWorld Health receives Orphan Drug Designation from the two leading regulatory agencies in the world, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for paromomycin injection to treat visceral leishmaniasis.
A Lehman Brothers Foundation grant helps accelerate identification of drug compounds for pediatric diarrheal disease.
OneWorld Health, in collaboration with the Special Programme for Research and Training in Tropical Diseases of the World Health Organization (WHO/TDR( completes a large Phase 3 clinical trial to cure visceral leishmaniasis using paromomycin.
The Bill & Melinda Gates Foundation awards $42.6 million to OneWorld Health for development of artemisinin through synthetic biology.
OneWorld Health partners with UC Berkeley and Amyris Biotechnologies with the goal of providing unlimited, affordable supplies of first-line antimalarial ingredient using synthetic biology.
The University of California Santa Barbara donates a patent for a discovery involving the novel use of calcium channel blockers to control the schistosomiasis parasite.
The Bill & Melinda Gates Foundation funds the development of a vaccine for the prevention and treatment of malaria. OneWorld Health selects Sanaria, Inc. as a partner.
The Chiron Foundation award grants to further studies in visceral leishmaniasis treatment and the Sapling Foundation awards a grant to study the feasibility of engaging pharmaceutical scientists in OneWorld Health drug development programs.
Collective licensing agreement is signed with the Special Programme for Research and Training in Tropical Disease (TDR) of the World Health Organization (WHO) to develop a new cure for visceral leishmaniasis.
Largest Phase 3 clinical trial for visceral leishmaniasis begins in India for paromomycin, an off-patent aminoglycoside antibiotic that has been marketed internationally for over 40 years.
Promising new compounds to treat Chagas infections are in-licensed from Yale University and the University of Washington .
The Bill & Melinda Gates Foundation funds the first two drug development projects for kala-azar (visceral leishmaniasis) and Chagas disease. The National Institute of Allergy and Infectious Diseases (NIAID) collaborates with OneWorld Health to develop Chagas disease drug lead.
OneWorld Health receives first in-licensing of promising new drug lead for Chagas disease from Celera Genomics.